Importance Low-molecular-weight heparin is recommended over warfarin for the treatment
of acute venous thromboembolism (VTE) in patients with active cancer largely based on …

PURPOSE: A substantial clinical need exists for an alternative to vitamin K antagonists for
treating deep-vein thrombosis in cancer patients who are at high risk of both recurrent …

Background Treatment of venous thromboembolism (VTE) in patients with cancer has a high
rate of recurrence and bleeding complications. Guidelines recommend low‐molecular …

The treatment of venous thromboembolism (VTE) in patients with cancer is challenging
because these patients have increased risks of both recurrent VTE and major bleeding …

Introduction Low-molecular-weight heparin (LMWH) and vitamin K antagonists (VKA) are
current treatment options for cancer patients suffering from acute venous thromboembolism …

Background Compared with people without cancer, people with cancer who receive
anticoagulant treatment for venous thromboembolism (VTE) are more likely to develop …

Background Low‐molecular‐weight heparin is the guideline‐endorsed treatment for cancer‐
associated venous thromboembolism (VTE). While apixaban is approved for the treatment of …

Background: Currently, low molecular weight heparin is the guideline endorsed treatment of
patients with cancer associated venous thromboembolism (VTE). While apixaban is …

International and national guidelines recommend low-molecular-weight heparin for the
treatment of venous thromboembolism (VTE) in patients with cancer. The aim of the …

This study evaluated enoxaparin alone versus initial enoxaparin followed by warfarin in
secondary prevention of venous thromboembolic events in adults with active malignancy …